Histopathological Assessment of Prostate Cancer Bone Osteoblastic Metastases
is companion of
- Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade
- Finnish Multicenter Study Comparing Intermittent to Continuous Androgen Deprivation for Advanced Prostate Cancer: Interim Analysis of Prognostic Markers Affecting Initial Response to Androgen Deprivation
Abstract
Purpose:
Many patients with prostate cancer have bone metastases that appear osteoblastic on radiography, and yet these patients are at increased risk for fracture. The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases.
Materials and Methods:
Histomorphometry was used to evaluate multisite bone biopsies in 12 patients who died with multiple bone metastases, of whom 7 had received bisphosphonate therapy.
Results:
Bone histomorphometry revealed a wide spectrum of cancer induced bone changes in different metastatic sites in individual patients, ranging from a pronounced osteodense to a pronounced osteopenic type. Each metastatic lesion was associated with various amounts of resorption. Decreased bone volume was seen in half of all biopsies. Osteodense lesions were largely composed of under mineralized woven bone, which increases the frailty of new bone. Interestingly woven bone was produced by alkaline phosphatase spindle-shaped cells arising from the connective stroma surrounding tumor cells. The bone response generally was similar in bisphosphonate treated patients and those who did not receive bisphosphonate.
Conclusions:
Despite the osteoblastic nature of bone metastases in prostate cancer, the osteolytic-osteopenic bone lesions found in each clinically osteoblastic case may explain the frequent fractures observed in these cases. In addition, the finding that woven bone formed directly from the tumor stroma and not from the adjacent bone surface supports further research into the mechanisms of abnormal bone formation in prostate cancer bone metastases.
References
- 1 : Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis2003; 20: 171. Google Scholar
- 2 : Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. BJU Int2001; 88: 231. Google Scholar
- 3 : New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem1996; 29: 67. Google Scholar
- 4 : Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem1999; 45: 1240. Google Scholar
- 5 : Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol1991; 68: 74. Google Scholar
- 6 : Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer2000; 82: 858. Google Scholar
- 7 : Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol2007; 177: 17. Link, Google Scholar
- 8 : Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res2006; 12: 6285s. Google Scholar
- 9 : Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol2003; 34: 646. Google Scholar
- 10 : Histochemistry and immunohistochemistry on bone marrow biopsies: A rapid procedure for methyl methacrylate embedding. Pathol Res Practice1995; 191: 121. Google Scholar
- 11 : Simultaneous demonstration of bone alkaline and acid phosphatase activities in plastic-embedded sections and differential inhibition of the activities. Histochemistry1987; 86: 559. Google Scholar
- 12 : Bone histomorphometry: standardization of nomenclature, symbols, and units: Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res1987; 2: 595. Google Scholar
- 13 :
Histomorphometric manifestations of age-related bone loss . In: The Aging Skeleton. Edited by . San Diego: Academic Press1999: 251. Google Scholar - 14 : Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol2005; 23: 4925. Google Scholar
- 15 : Relationship between tissue stiffness and degree of mineralization of developing trabecular bone. J Biomed Mater Res A2008; 84: 508. Google Scholar
- 16 : RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res2003; 18: 1088. Google Scholar
- 17 : Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol2001; 170: 451. Google Scholar
- 18 : Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003; 169: 2008. Link, Google Scholar
- 19 : Giant osteoclast formation after long-term oral aminobisphosphonate therapy for postmenopausal osteoporosis. J Bone Miner Res2007; 22: S17. Google Scholar
- 20 : Unusual osteoclast morphology in teriparatide treated patients who have been pretreated with alendronate. J Bone Miner Res2007; 22: S29. Google Scholar
